HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis study followed 49 adults with advanced HER2-positive breast cancer who had already tried at least two other treatments. They received a combination of tucatinib, trastuzumab, and capecitabine in a real-world setting. The goal was to see how the treatment affected their quali…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
Custom vaccine trains immune system to fight aggressive breast cancer
Disease control CompletedThis early-phase study tested a personalized vaccine made from a patient's own immune cells, designed to target HER2-positive breast cancer. 31 adults with stage II or III breast cancer received the vaccine alongside standard chemotherapy before surgery. The goal was to see if th…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis study tested a combination of two drugs, tucatinib and trastuzumab deruxtecan (T-DXd), in 70 people with advanced HER2-positive breast cancer that had spread or couldn't be removed by surgery. The goal was to see how well the drugs worked together to shrink tumors and what s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis study tested a new drug, copanlisib, combined with the standard drug trastuzumab in 26 women with advanced HER2-positive breast cancer that had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors or s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New study tests targeted therapy for aggressive breast cancer in egyptian women
Disease control CompletedThis study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer, an aggressive type. Researchers followed 80 patients to see if single or combination therapy improved survival and safety. The goal was to understand real-world effectiveness in…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Deraya University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Completed study examines Real-World use of neratinib in early breast cancer
Knowledge-focused CompletedThis study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received neratinib as an extra treatment after their initial therapy. The goal was to describe the patients' characteristics, such as age, tumor details, and health history. It did …
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Pierre Fabre Medicament • Aim: Knowledge-focused
Last updated May 26, 2026 04:18 UTC
-
Real-world data reveals how often breast cancer patients stop or adjust T-DXd therapy
Knowledge-focused CompletedThis study looked at 22 adults with advanced HER2-positive or HER2-low breast cancer who were taking the drug trastuzumab deruxtecan (T-DXd). Researchers wanted to see how often patients stopped treatment early or needed dose changes in everyday medical practice. The goal was to …
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC